Article type: Short communication Title: Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains Authors:

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission with several emerging variants remain uncontrolled in many countries, indicating the pandemic remains severe. Recent studies showed reduction of neutralization against these emerging SARS-CoV-2 variants by vaccine-elicited antibodies. Among those emerging SARS-CoV-2 variants, a panel of amino acid mutations was characterized including those in the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein. In the present study, we evaluated our previously identified antibody and antibody domains for binding to these RBD variants with the emerging mutations, and neutralization of pseudo typed viruses carrying spike proteins with such mutations. Our results showed that one previously identified antibody domain, ab6, can bind 32 out of 35 RBD mutants tested in an ELISA assay. All three antibodies and antibody domains can neutralize pseudo typed B.1.1.7 (UK variant), but only the antibody domain ab6 can neutralize the pseudo typed virus with the triple mutation (K417N, E484K, N501Y). This domain and its improvements have potential for therapy of infections caused by SARS-CoV-2 mutants.

[1]  A. Iafrate,et al.  Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity , 2021, Cell.

[2]  M. Mulligan,et al.  Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies , 2021, bioRxiv.

[3]  D. Ho,et al.  Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, Research square.

[4]  Vineet D. Menachery,et al.  Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera , 2021, bioRxiv.

[5]  D. Ho,et al.  Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization , 2021, bioRxiv.

[6]  B. Graham,et al.  mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants , 2021, bioRxiv.

[7]  A. García-Sastre,et al.  The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera , 2021, medRxiv.

[8]  Vineet D. Menachery,et al.  Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape , 2021, Nature communications.

[9]  William T. Harvey,et al.  SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies , 2021, medRxiv.

[10]  L. Morris,et al.  SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.

[11]  M. Nussenzweig,et al.  mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, bioRxiv.

[12]  P. Dormitzer,et al.  Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.

[13]  J. Bloom,et al.  Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies , 2021, bioRxiv.

[14]  Sergei L. Kosakovsky Pond,et al.  Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.

[15]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[16]  P. Rocchi,et al.  Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting , 2020, Molecular Cell.

[17]  Haiyong Peng,et al.  SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity , 2020, Nature Communications.

[18]  M. Beltramello,et al.  The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity , 2020, bioRxiv.

[19]  Lisa E. Gralinski,et al.  Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection , 2020, Proceedings of the National Academy of Sciences.

[20]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[21]  S. Subramaniam,et al.  High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models , 2020, Cell.

[22]  P. Rocchi,et al.  Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting , 2020, Molecular Cell.

[23]  C. Rice,et al.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.

[24]  D. Dimitrov,et al.  Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold , 2020, mAbs.

[25]  D O Morgan,et al.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.

[26]  R. Andino,et al.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses , 1994, Journal of virology.